Darunavir + Raltegravir + Etravirine = High Rate of Treatment Success
Ninety percent of highly treatment-experienced patients who received this combination achieved virologic suppression at week 24; results were sustained at week 48.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)